- Home
- EQT vs ROIV Comparison
EQT vs ROIV Comparison
Compare EQT & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQT | ROIV |
|---|---|---|
| Founded | 1925 | 2014 |
| Country | United States | United Kingdom |
| Employees | 1873 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9B | 26.1B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EQT | ROIV |
|---|---|---|
| Price | $53.89 | $36.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 9 |
| Target Price | ★ $69.15 | $28.94 |
| AVG Volume (30 Days) | ★ 5.6M | 5.4M |
| Earning Date | 04-21-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 635.56 | N/A |
| EPS | ★ 2.70 | N/A |
| Revenue | ★ $8,644,211,000.00 | $8,260,000.00 |
| Revenue This Year | $20.28 | N/A |
| Revenue Next Year | N/A | $744.61 |
| P/E Ratio | $19.87 | ★ N/A |
| Revenue Growth | ★ 63.92 | N/A |
| 52 Week Low | $47.94 | $11.60 |
| 52 Week High | $68.24 | $37.97 |
Technical Indicators
Market Signals| Indicator | EQT | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 60.54 |
| Support Level | $53.37 | $33.01 |
| Resistance Level | $54.87 | $37.00 |
| Average True Range (ATR) | 1.27 | 1.21 |
| MACD | 0.05 | 0.15 |
| Stochastic Oscillator | 64.74 | 79.45 |
Price Performance
Historical ComparisonAbout EQT EQT Corporation
EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and its transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.